Lutz Froelich
Overview
Explore the profile of Lutz Froelich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
3719
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abu-Rumeileh S, Scholle L, Mensch A, Grosskopf H, Ratti A, Kolsch A, et al.
Nat Commun
. 2025 Mar;
16(1):2019.
PMID: 40044663
Blood phosphorylated (p)-tau 181 and p-tau 217 have been proposed as accurate biomarkers of Alzheimer's disease (AD) pathology. However, blood p-tau 181 is also elevated in amyotrophic lateral sclerosis (ALS)...
2.
Mendes A, Herrmann F, Bergh S, Cesana B, Handels R, Ciccone A, et al.
J Am Med Dir Assoc
. 2024 Nov;
26(2):105374.
PMID: 39608404
Objectives: Dementia significantly impacts quality of life, health care costs, and caregiver burden, being a leading cause of death among older adults. We investigated predictors of mortality in people with...
3.
Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D, et al.
JAMA Neurol
. 2024 Nov;
81(12):1304-1311.
PMID: 39483064
Importance: Since 2018, a movement has emerged to define Alzheimer disease (AD) as a purely biological entity based on biomarker findings. The recent revision of the Alzheimer's Association (AA) criteria...
4.
Cesana B, Bergh S, Ciccone A, Cognat E, Fabbo A, Fascendini S, et al.
J Alzheimers Dis
. 2024 Mar;
98(3):1043-1052.
PMID: 38489173
Background: Nursing home placement (NHP) can be the final step of patients with Alzheimer's disease. Objective: We aimed to identify NHP predictors among 508 people with dementia with a 3-year...
5.
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
Frisoni G, Festari C, Massa F, Ramusino M, Orini S, Aarsland D, et al.
Lancet Neurol
. 2024 Feb;
23(3):302-312.
PMID: 38365381
The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders...
6.
Muurling M, Pasmooij A, Koychev I, Roik D, Froelich L, Schwertner E, et al.
PLoS One
. 2023 Nov;
18(11):e0294797.
PMID: 37972073
[This corrects the article DOI: 10.1371/journal.pone.0285807.].
7.
Mendes A, Bergh S, Cesana B, Handels R, Ciccone A, Cognat E, et al.
J Alzheimers Dis
. 2023 Nov;
96(3):1083-1096.
PMID: 37927262
Behavioral and psychological symptoms of dementia (BPSD) bring complexity in the clinical management of people with dementia; therefore, it is important to evaluate different models of care, such as Special...
8.
Muurling M, Pasmooij A, Koychev I, Roik D, Froelich L, Schwertner E, et al.
PLoS One
. 2023 Jul;
18(7):e0285807.
PMID: 37418385
Introduction: Clinical research with remote monitoring technologies (RMTs) has multiple advantages over standard paper-pencil tests, but also raises several ethical concerns. While several studies have addressed the issue of governance...
9.
Novak P, Kovacech B, Katina S, Schmidt R, Scheltens P, Kontsekova E, et al.
Nat Aging
. 2023 Apr;
1(6):521-534.
PMID: 37117834
Alzheimer's disease (AD) pathology is partly characterized by accumulation of aberrant forms of tau protein. Here we report the results of ADAMANT, a 24-month double-blinded, parallel-arm, randomized phase 2 multicenter...
10.
de Rojas I, Moreno-Grau S, Tesi N, Grenier-Boley B, Andrade V, Jansen I, et al.
Nat Commun
. 2023 Feb;
14(1):716.
PMID: 36759603
No abstract available.